Cetuximab dose-escalation study in patients with metastatic colorectal cancer with no or slight skin reactions on cetuximab standard dose treatment (EVEREST)

Trial Profile

Cetuximab dose-escalation study in patients with metastatic colorectal cancer with no or slight skin reactions on cetuximab standard dose treatment (EVEREST)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Cetuximab; Irinotecan
  • Indications Colorectal cancer
  • Focus Pharmacokinetics; Therapeutic Use
  • Acronyms EVEREST
  • Sponsors Merck KGaA
  • Most Recent Events

    • 15 May 2008 Results will be presented at ASCO 2008 according to a ImClone Systems media release.
    • 15 Feb 2007 Preliminary results have been reported.
    • 14 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top